



FEMSELECT INVESTOR UPDATE





AGENDA

- 1. High-level Updates
- 2. Round B Progress and Revenue Model
- 3. Clinical Update
- 4. Field Update

Pre-COVID HIGH-LEVEL

UPDATES

- ▲ Very successful CLA raise
- ▲ Physician Professional Education program going well
 - ▲ Gynesim-enabled wet labs—physicians lining up to be trained
- ▲ Ended 2019 with sales of \$70,000
- ▲ 7 Value Analysis Committee (VAC) Approvals
- ▲ 3 new IP allowances issued
- VC engagement without a banker inefficient. To ensure financing in 2020, engaging with banker.
- Strategics cautiously optimistic but want to see additional data (both clinical and commercial)

Post-COVID-19

High-Level Update

- ▲ Very successful CLA raise—\$1.2M in the bank; \$.8M pending
- ▲ Elective Procedures on hold yet "COVID-friendly" procedure w/no hospital stay
- ▲ Small nimble company—easy to conserve cash
 - ▲ Work continues on infrastructure without travel or high promotion costs
- ▲ CRO working on remote monitoring
- ▲ Commercial site availability already as well as several VACs in motion
- ▼ Will be slower to get into hospitals due to COVID
- ▼ Strategics will be more risk adverse for remainder of the year ?
- ▼ Raising money likely to slow down

CLA Update:

TOTAL RAISED IN CLA =

\$1.2MM+ ?pending

CASH BURN = \$100-\$150K

depending on scenario

MONTHS OF CASH = 10-12

RUNWAY/BUDGET

► Q2

- HUNKER DOWN
- FOCUS ON FINANCIAL DUE DILIGENCE AND TRAINING PROGRAM PREPARATION

► Q3

 INCREASED BUDGET AS TRAVEL RESTRICTIONS EASE AND ELECTIVE PROCEDURES RESUME

► Q4

► CLOSE FUNDING/1ST TRANCHE

FUNDING STRATEGY LEADING TO **ACQUISITION**




CLOSED: FEBRUARY 28, 2018

SECURITIES: SERIES A PREFERRED SHARES

POST-MONEY VALUATION: \$10 MILLION

EXIT OPPORTUNITIES



PROGRESS ROUND B/CLA

PROGRESS ON ROUND B DISCUSSIONS: VENTURES GROUPS FEEDBACK & LEARNINGS

- Engaging with Investment Banker to work on fundraising/M&A activity
- Bankers and VC's are available for DD and have capital that must be deployed
- ✤ Capital raise of \$15M necessary
- Updated revenue model and 2-3 years time horizon to Exit
- Want to see more clinical data—with COVID, now can be done remotely
- Build a commercial organization

Financial Model Assumptions

Sales Reps:	6-8 Reps hired July 1 (model was built pre-COVID)
-------------	---

Physician targets: Female Pelvic Medicine and Reconstructive Surgery (FPMRS) Specialists

Total targets: 2,500 (22% reached by 2023)

Price: \$1400 increasing to \$1800


COGS: \$410/unit through mid-2021 (Transfer to Mass Production complete)

COGS post-transfer: \$80


24 month ramp: Each rep achieves 30 "active" physicians within initial 24 mos of hire

"Active" = Physician is trained, product is approved (thru VAC) & ramp-up achieved of identifying patient types.

TRAJECTORY OF ENPLACE




ROUND B USE OF PROCEEDS



COMPARABLE EXITS IN **WOMEN'S HEALTH + UROLOGY**


ACQUIRER	ACQUIRED COMPANY	DATE	ACQUISITION PRICE
LABORIE	COGENTIX MEDICAL	APR 2018	\$214M*
seientific	NxTHERA	APR 2018	\$306M
s Boston Scientific	nVISION	APR 2018	\$275M
Teleflex®	NEOTRACT INC.	SEP 2017	\$725M (\$1.1B + milestones)
<u>CoperSurgical</u>	PARAGARD IUD FROM TEVA	SEPT 2017	\$1.1B
	NUELLE	MAY 2017	Undisclosed
Medtronic	Smith & NEPHEW'S GYN BUSINESS	MAY 2016	\$350M

KEY COMMERCIAL MILESTONES



IP UPDATE NEW ALLOWANCES

STRONG IP PORTFOLIO: 4 FAMILIES



CLINICAL UPDATE

CLINICAL	
OVERVIEW	

175+ patients treated with EnPlace

2015		15 clinical patients
2018	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	20 clinical patients 5 commercial patients
2019		Å Å Å Å Å Å Å Å Å Å Å Å Å Å Å Å Å
		47 clinical patients 60 commercial patients
2020		30 commercial patients Pre-COVID-19

FIELD UPDATE

US Commercialization

- Routinely conducting peer-to-peer workshops for prospective physicians to observe multiple cases.
- Held two (GyneSim) pelvic model "wet labs" w/ approach for single/multiple physician training – professionally positioned like Intuitive, Storz, etc.
- Leads stem from shows (AUGS, SGS, ACOG), prior relationships & online inquiries.
- eLearning module program to launch w/ SGS leads (Q2) – will ask all physician/leads for participation.

FEMSELECT | CONFIDENTIAL

Sales/units update

- VAC "approved" at 7 locations
- VAC "in review" in 4 additional locations
- VAC "proposed" in 5 additional locations
- VAC's routinely requiring 120+ days
- Customer service "in motion"
- Integrating 5mm product in sites



OUS Overview

- Exploring licensing and distribution
 - opportunities in select
 - European countries
- Contracting phase
 with Israeli distributor
 for Q3 launch in Israel

Israeli Update

- ► Sales 2019: 28
- Sales 2020 (through March) 13
- Largest Sick Fund is reviewing EnPlace and has asked for cases from 3 of its hospitals
- Should be able to move forward there by end of Q2





THANK YOU

THE FEMSELECT BOARD OF DIRECTORS



DR. PETER FITZGERALD TRIVENTURES

- Co-Founder & Managing Partner, Triventures
- Director, Center for Cardiovascular Technology, Stanford University



DR. MICHELLE LIN TRANSPACIFIC VENTURES

- Founder and General Partner, TransPacific Ventures, (TPV)
- Director, TSC Bio-venture Inc. and various other start-ups



- CARMIZISAPEL RADBIOMED COO, Innercore Medical
- Former Director of Business Development and Portfolio Analysis, RAD BioMed Accelerator



BERNIE RUDNICK MID-ATLANTIC BIO ANGELS (MABA) AND KEIRETSU ANGEL GROUP

- Founder and Managing Partner of CapGenic Advisors, LLC
- Founder MABA and LP in 4 funds Investment Committee of 2
- Director, Atrin Pharmaceuticals, Axxia Pharma, SageMedic, Virion Tx, Co-Founder OtoSense (now ADI)



RENEE SELMAN FORMER WORLDWIDE PRESIDENT, ETHICON WOMEN'S HEALTH AND UROLOGY

- Industry expert and Angel investor, Robin Hood Ventures
- Former Interim Chief Commercial Officer of Agile Therapeutics (women's health)
- Former Worldwide President of Ethicon Women's Health and Urology (division of J&J)



MAX KORENVAES KORENVAES FAMILY FUND

- Director, Double Helix Management, Apollo Laboratories
- and Xhale Asssurance



DR. HAMPTON RICHARDS KORENVAES FAMILY FUND (OBSERVER)

- OB-GYN Advisor to Korenvaes
- Private practice at Walnut Hill OBGYN

THE FEMSELECT TEAM, OVER 100 YEARS OF DIVERSE EXPERIENCE



DEBBIE GARNER CO - CHIEF EXECUTIVE OFFICER

- 20+ years of experience in commercialization roles in pharma and medical device companies including Eli Lilly and Co. and iMDsoft
- MBA, Wharton School of Business, University of Pennsylvania and BA, Harvard College



RENEE SELMAN CO - CHIEF EXECUTIVE OFFICER

- Industry expert and Angel investor, Robin Hood Ventures
- Former Interim Chief Commercial Officer of Agile Therapeutics (women's health)
- Former Worldwide President of Ethicon Women's Health and Urology (division of J&J)



MENAHEM NEUMAN MEDICAL DIRECTOR

- Head of Urogynecology, Galilee Medical Center and Bar-Ilan University
- Former Ethicon Women's Health & Urology PFR global trainer and Pelvic Floor Innovation Committee Member



JOEL CHECHIK CHIEF COMMERCIAL OFFICER

- 20 years of experience in Sales and Marketing roles for Coloplast, Medtronic and, most recently, NeoTract
- Led targeted marketing and sales expansion initiatives for a variety of minimally invasive, cardiac and urologic implantable technologies.



BOAZ HARARI VICE PRESIDENT, R + D

- 20+ years of experience in the medical device field
- Former CTO VibeMedic Ltd. and Niti Surgical Solutions Ltd.
- Experienced engineer who has developed numerous clinical devices from concept to market

2020 KEY HIRES: CHIEF MEDICAL OFFICER | DIRECTOR OF MARKETING | DIRECT SALES REPS